CROI 2015 Program and Abstracts

Poster Listings

552 Second-Line Treatment in Sub-Saharan Africa: Week 144 Follow-up of the EARNEST Trial James G. Hakim 1 ; JenniferThompson 2 ; Cissy M. Kityo 3 ; SarahWalker 2 ; Joep van Oosterhout 4 ; Anne Hoppe 2 ; Andrew D. Kambugu 5 ; Peter Mugyenyi 3 ; Nicholas Paton 6 On behalf of the EARNESTTrialTeam 1 University of Zimbabwe, College of Health Sciences, Harare, Zimbabwe; 2 University College London, London, United Kingdom; 3 Joint Clinical Research Centre, Kampala, Uganda; 4 Dignitas, Zomba, Zomba, Malawi; 5 Infectious Disease Institute, Kampala, Uganda; 6 National University of Singapore, Singapore, Singapore; 7 MRC Clinical Trials Unit at University College London, London, United Kingdom 553 Withdrawing Inactive NRTIs in Subjects With Suppressed Viremia: A Randomized Trial Josep M. Llibre 1 ; Hortensia Alvarez 8 ; Antonio Antela 2 ; JessicaToro 1 ; Juan González-Moreno 3 ; M Jesús Perez-Elias 4 ; Arkaitz Imaz 5 ; Mar Masià 6 ; Manel Crespo 7 ; Bonaventura Clotet 1 1 Univ Hosp Germans Trias, Badalona, Spain; 2 Hospital Clínico Universitario, Santiago de Compostela, Spain; 3 Hospital Son Llàtzer, Mallorca, Spain; 4 Hospital Ramón y Cajal, IRYCIS, Madrid, Spain; 5 Hospital Universitari de Bellvitge, L’Hospitalet de Llobregat, Spain; 6 Hospital Universitario de Elche, Elche, Spain; 7 Hospital Universitari Vell d’Hebró, Barcelona, Spain; 8 Complejo Universitario de Ferrol, A Coruña, Spain 554LB Cabotegravir and Rilpivirine As 2-Drug Oral Maintenance Therapy: LATTE W96 Results David A. Margolis 1 ; Cynthia C. Brinson 2 ; Graham H. Smith 3 ; Jerome deVente 4 ; Debbie P. Hagins 5 ; Sandy K. Griffith 1 ; Marty H. St. Clair 1 ; KimberlyY. Smith 6 ; Peter E.Williams 7 ;William R. Spreen 1 1 GlaxoSmithKline, Durham, NC, US; 2 Central Texas Clinical Research, Austin, TX, US; 3 Maple Leaf Medical Clinic, Toronto, Canada; 4 Living Hope Foundation, Long Beach, CA, US; 5 Chatham County Health Department, Savannah, GA, US; 6 ViiV Healthcare, Durham, NC, US; 7 Janssen Pharmaceuticals, Inc, Beerse, Belgium 2:30 pm– 4:00 pm ART: Adherence, Adherence, Adherence 555 Self-Reported Versus Blood-Tested ART Intake to Estimate ART Coverage in South Africa Helena Huerga 1 ; GillesVan Cutsem 2 ; LubbeWiesner 3 ; Malika Bouhenia 1 ; Jihane Ben Farhat 1 ; Emmanuel Fajardo 2 ; Ruggero G. Giuliani 2 ; David Maman 1 ;Thomas Ellman 2 ; Jean- François Etard 1 1 Epicentre, Paris, France; 2 Médecins Sans Frontières, Cape Town, South Africa; 3 University of Cape Town, Cape Town, South Africa 556 Real-Time Electronic Adherence Monitoring and Risk of Viral Rebound Jessica E. Haberer 1 ; Nicholas Musinguzi 2 ; Mark Siedner 1 ;Yap Boum 3 ; PeterW. Hunt 4 ; Jeffrey Martin 4 ; David R. Bangsberg 1 1 Massachusetts General Hospital, Harvard Medical School, Boston, MA, US; 2 Mbarara University of Science and Technology, Mbarara, Uganda; 3 Médecins Sans Frontières, Mbarara, Uganda; 4 University of California San Francisco, San Francisco, CA, US 557 Determinants of Adherence to Antiretroviral Therapy Differ Between Africa and Asia Rimke Bijker 1 ; Awachana Jiamsakul 2 ; Margaret Siwale 3 ; Sasisopin Kiertiburanakul 4 ; Cissy M. Kityo 5 ; Praphan Phanuphak 6 ;Tobias F. Rinke deWit 1 ; OonTek Ng 7 ; Raph L. Hamers 1 ; 1 Amsterdam Institute for Global Health and Development, Amsterdam, Netherlands; 2 The Kirby Institute, Sydney, Australia; 3 Lusaka Trust Hospital, Lusaka, Zambia; 4 Ramathibodi Hospital, Mahidol University, Bangkok, Thailand; 5 Joint Clinical Research Centre, Kampala, Uganda; 6 HIV-NAT/Thai Red Cross AIDS Research Centre, Bangkok, Thailand; 7 Tan Tock Seng Hospital, Novena, Singapore 558 Retention on Antiretroviral Therapy by Sex and Pregnancy Status in a Large Cohort of HIV-Infected Patients in Rural Nigeria Usman I. Gebi 2 ; Meridith Blevins 1 ; MukhtarY. Muhammad 2 ; C.WilliamWester 1 ; Muktar H. Aliyu 1 1 Vanderbilt University, Nashville, TN, US; 2 Friends for Global Health Initiative Nigeria, Abuja, Nigeria Session P-K1 Poster Session Poster Hall PASER-TASER Cohort Collaboration 1 PASER-TASER Cohort Collaboration

559 Randomised Controlled Trial of Text-Message Dosing Reminders in Patients Starting ART Catherine Orrell 1 ; Karen Cohen 1 ; Katya Mauff 1 ; David R. Bangsberg 2 ; Gary Maartens 1 ; Robin Wood 1 1 University of Cape Town, Cape Town, South Africa; 2 Harvard Medical School, Boston, MA, US 560 Socioeconomic Factors and Virological Rebound: A Prospective UK Cohort Study Lisa S. Burch 1 ; Colette Smith 1 ; Jane Anderson 3 ; Lorraine Sherr 1 ; Alison Rodger 1 ; Richard GIlson 1 ; Jonathan Elford 2 ; Andrew N. Phillips 1 ; Margaret Johnson 4 ; Fiona Lampe 1 ASTRA (Antiretrovirals, SexualTransmission Risk and Attitudes) 1 University College London, London, United Kingdom; 2 City University London, London, United Kingdom; 3 Homerton University Hospital NHS Foundation Trust, London, United Kingdom; 4 Royal Free London NHS Foundation Trust, London, United Kingdom 2:30 pm– 4:00 pm ART: Monitoring and Biomarkers 561 NewMarker of Standard-of-ART Care: Percentage of Time on cART With Suppressed HIV-RNA Kamilla G. Laut 1 ; Leah C. Shepherd 4 ; Court Pedersen 2 ; Jürgen Rockstroh 3 ; Helen Sambatakou 5 ; Dzmitry Paduta 6 ; Jens D. Lundgren 1 ; Amanda Mocroft 4 ; Ole Kirk 1 ; EuroSIDA in EuroCoord 1 on behalf of EuroSIDA in EuroCoord 1 Rigshospitalet, University of Copenhagen, Copenhagen, Denmark; 2 Odense University Hospital, Odense, Denmark; 3 University Hospital Bonn, Bonn, Germany; 4 University College London, London, United Kingdom; 5 Hippokration General Hospital, University of Athens, Athens, Greece; 6 Gomel Regional Centre for Hygiene, Gomel, Belarus 562 Viremia Copy Years and Its Impact on Risk of Clinical Progression According to Shape Alessandro Cozzi-Lepri 1 ; Antonella Cingolani 2 ; Andrea Antinori 3 ; Andrea De Luca 4 ; Cristina Mussini 5 ; Stefano Rusconi 6 ; Carmela Pinnetti 3 ; Massimo Galli 6 ; Antonella Castagna 8 ; Antonella d’Arminio Monforte 7 1 University College London, London, United Kingdom; 2 Sacro Cuore University, Roma, Italy; 3 INMI Spallanzani, Roma, Italy; 4 University of Siena, Siena, Italy; 5 University of Modena, Modena, Italy; 6 Luigi Sacco University Hospital, Milano, Italy; 7 S. Paolo Hospital, Milano, Italy; 8 San Raffaele Scientific Institute, Milano, Italy 563 Monitoring and Switching of Antiretroviral Therapy in Sub-Saharan Africa Andreas D. Haas 1 ; Olivia Keiser 1 ; François Dabis 2 ; Mary-Ann Davies 3 ; Rosalind M. Parkes- Ratanshi 4 ; Steven J. Reynolds 5 ; KaraWools-Kaloustian 6 ; GillesWandeler 1 ; Matthias Egger 1 IeDEA East,West and Southern Africa 1 Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland; 2 Université Bordeaux, Bordeaux, France; 3 University of Cape Town, Cape Town, South Africa; 4 Makerere University College of Health Sciences, Makerere, Uganda; 5 National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, MD, US; 6 Indiana University, Indianapolis, IN, US 564 Virological Factors AssociatedWith Outcome of Dual MVC/RAL Therapy (ANRS-157 Trial) Cathia Soulie 1 ; Lambert Assoumou 2 ; Melanie Darty 3 ; Christophe Rodriguez 3 ; Gilles Peytavin 4 ; Marc-AntoineValantin 5 ; Dominique Costagliola 2 ; Christine Katlama 5 ;Vincent Calvez 1 ; Anne-Genevieve Marcelin 1 1 Hôpital Pitié Salpêtrière, Paris, France; 2 INSERM/UPMC, Paris, France; 3 APHP Mondor, Creteil, France; 4 APHP Bichat, Paris, France; 5 Hôpital Saint-Louis, APHP, Université Paris Diderot, Paris, France 565 D-dimer Doesn’t Return to Pre-HIV Levels After Therapy and Is Linked With HANA Events Matthew S. Freiberg 2 ; Ionut Bebu 4 ; RussellTracy 3 ; Jason F. Okulicz 1 ; Anuradha Ganesan 1 ; Adam Armstrong 5 ;Thomas O’Bryan 1 ; Brian K. Agan 1 IDCRP HIVWorking Group 1 Uniformed Services University of the Health Sciences, North Bethesda, MD, US; 2 Vanderbilt University Medical Center, Nashville, TN, US; 3 University of Vermont College of Medicine, Burlington, VT, US; 4 The George Washington University, Rockville, MD, US; 5 US Naval Medical Research Unit No. 6 Peru, Lima, Peru Session P-K2 Poster Session Poster Hall

Poster Listings

46

CROI 2015